Navigation Links
Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
Date:9/11/2007

ficer of Anadys. "In chronic viral diseases, achieving blood levels in preclinical studies that are many-fold above concentrations needed for viral suppression is generally recognized as a predictor of potential clinical utility."

In June, Anadys announced the nomination of ANA598 as a clinical development candidate. ANA598 was selected from the Company's internal NS5B discovery efforts based on an optimized balance of preclinical properties and was the result of the Company's structure-based drug design capabilities. ANA598 is undergoing IND enabling activities and an IND submission is targeted for the first half of 2008.

"After completing the necessary IND enabling studies, we look forward to exploring the potential clinical utility of ANA598 in patients with HCV," said James Freddo, MD, Anadys' Chief Medical Officer. "Based on the combined potency, pharmacokinetic and preliminary toxicologic properties of ANA598, we believe that this is an exciting new direct antiviral to investigate for the treatment of patients with hepatitis C virus infection."

About Anadys

Anadys Pharmaceuticals, Inc. is a biopharmaceutical company committed to advancing patient care by developing and commercializing novel small molecule medicines for the treatment of hepatitis C virus (HCV) infection and cancer. The Company is developing ANA598, a small-molecule, non-nucleoside inhibitor of the NS5B polymerase for the treatment of HCV and ANA773, an oral TLR7 agonist prodrug for cancer.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to the expected timing and planned development activities for ANA598, the prediction that ANA598 has a low likelihood of producing clinical drug-drug interactions, the use of doses in preclinical studies that are designed to be predictive of human doses, the belief that achievin
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule, Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for Clinical Development in Chronic Hepatitis C Virus Infection
2. Anadys Reports Preclinical Data Showing ANA773 Promotes Anti-Tumor Activity of Natural Killer Cells
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... Aug. 3, 2015 VWR (NASDAQ: ... and solutions, announces the redesign of its global website, ... When visiting the new site, guests will enjoy enhanced ... and vivid images.  Each country site now includes: ... Z product menu; and , the ability to search ...
(Date:8/3/2015)... -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK ) today announced ... Investor Conference Call and webcast at 4:30 p.m., Eastern time, ... cover an update on Merrimack,s progress as well as ... release detailing the information to be discussed on the ... 10. Investors and the general public are invited to ...
(Date:8/3/2015)... and FLORHAM PARK, N.J. , Aug. ... naldemedine met its primary and secondary endpoints in a ... opioid-induced constipation (OIC) in adult patients with chronic non-cancer ... receptor antagonist (PAMORA). This is the third Phase III ... secondary endpoints. Study results showed that a ...
Breaking Medicine Technology:VWR's New Website Redesign Provides Improved Functionality for Customers 2Merrimack Pharmaceuticals Announces Timing of Second Quarter 2015 Investor Conference Call 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4
... , PARSIPPANY, N.J. , Jan. 14 ... the spine market, the company has announced the addition of ... individuals filling these positions bring a deep knowledge of the ... developing strong distribution networks in their respective areas.   , ...
... , , ... Jan. 14 ImproMed, Inc. creators of the Infinity ... home delivery services on behalf of veterinarians, announce the integration ... immediately with the release of v4.5 of Infinity, veterinarians can ...
Cached Medicine Technology:Custom Spine Announces the Expansion of its Sales Management Team 2VetCentric and ImproMed, Inc.(R) Announce One-Click Home Delivery Integration 2VetCentric and ImproMed, Inc.(R) Announce One-Click Home Delivery Integration 3
(Date:8/3/2015)... ... August 04, 2015 , ... Approved provider ... line up of live courses for the month of August. , Physical therapy ... individually or by purchasing a Physical Therapy Flex package. Flex packages allow therapists ...
(Date:8/3/2015)... ... August 03, 2015 , ... Sutter Health’s California Pacific Medical ... (COO) at CPMC. Hamila will start in her role effective immediately and will have ... has worked at CPMC and Sutter Health for about 15 years, including the past ...
(Date:8/3/2015)... ... August 03, 2015 , ... The Workgroup for Electronic Data ... IT to create efficiencies in healthcare information exchange, announced the release of its findings ... and Human Services (HHS) Secretary, WEDI shared survey results and recommendations ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... ruled in favor of the firm’s client Rebecca Hamsher, deciding that in accordance ... must reimburse benefits for Hamsher’s residential treatment for bulimia, depression and other mental ...
(Date:8/3/2015)... ... August 03, 2015 , ... A recent ... an overwhelming number of Hispanics believe people can positively affect their diabetes, few ... participants queried said making diet changes was important. Far fewer participants mentioned the ...
Breaking Medicine News(10 mins):Health News:Elite Online CE Provider Announces Schedule of Live Courses For Florida Physical Therapy Continuing Education 2Health News:Elite Online CE Provider Announces Schedule of Live Courses For Florida Physical Therapy Continuing Education 3Health News:Hamila Kownacki, RN Appointed as New Chief Operating Officer at CPMC 2Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 2Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 3Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 4Health News:Kantor & Kantor Announces North Cypress Medical Center Must Reimburse Benefits for Mental Health Treatment 2Health News:Kantor & Kantor Announces North Cypress Medical Center Must Reimburse Benefits for Mental Health Treatment 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 2Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 4
... The National Patient Safety Foundation,(NPSF) today announced that ... leading health care solutions providers to work,alongside the ... their families -- all with the single convergent ... http://www.newscom.com/cgi-bin/prnh/20080307/AQF053LOGO ), "We are excited to be ...
... of Pennsylvania School of Medicine can now explain how ... in the blood stream at any one time. These ... fight infections. , "There is a steady state number ... says senior author Michael P. Cancro, PhD, Professor of ...
... with inflammatory diseases such as rheumatoid arthritis now have ... biologic disease-modifying antirheumatic drugs (DMARDs). These drugs, derived by ... of the disease rather than simply treating the symptoms. ... because a one month,s supply may cost 100 times ...
... Henri de Toulouse-Lautrec suffered, is a genetic disease characterized ... window into how joints are destroyed by arthritis. It ... cathepsin K which hampers osteoclasts (the cells that break ... poor bone resorption and dense, brittle bones. , ...
... Co-Pays, HOUSTON, Nov. 4 US Oncology today ... pharmacy, has,exceeded the $10 million mark in assisting more ... Care Advantage in August 2006., "It was important ... patient access to oral chemotherapies by easing the financial,burdens ...
... MYL ),today announced that its subsidiary Mylan ... and Drug Administration (FDA) for its,Abbreviated New Drug ... and 750 mg. Levetiracetam Tablets are the generic ... Mylan,s Vice Chairman and CEO, commented: "We are,extremely ...
Cached Medicine News:Health News:AmerisourceBergen Joins National Patient Safety Foundation Corporate Council 2Health News:Penn scientists show how body determines optimal amount of germ-fighting B cells 2Health News:Medicaid policies vary widely for rheumatoid arthritis drugs 2Health News:Genetic disorder sheds light on enzyme's role in bone metabolism 2Health News:OncologyRx Care Advantage(TM) Specialty Pharmacy Passes $10 Million Milestone in Patient Financial Assistance 2Health News:OncologyRx Care Advantage(TM) Specialty Pharmacy Passes $10 Million Milestone in Patient Financial Assistance 3Health News:Mylan Receives Final Approval for First-to-File Generic Version of Antiepileptic Keppra(R) and Launches Immediately 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: